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Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. The use of experimental models of DN has
provided valuable information regarding many aspects of DN, including pathophysiology, progression, implicated genes, and new
therapeutic strategies. A large number of mouse models of diabetes have been identiﬁed and their kidney disease was characterized
to various degrees. Most experimental models of type 2 DN are helpful in studying early stages of DN, but these models have
not been able to reproduce the characteristic features of more advanced DN in humans such as nodules in the glomerular tuft or
glomerulosclerosis. The generation of new experimental models of DN created by crossing, knockdown, or knockin of genes
continues to provide improved tools for studying DN. These models provide an opportunity to search for new mechanisms
involving the development of DN, but their shortcomings should be recognized as well. Moreover, it is important to recognize
that the genetic background has a substantial eﬀect on the susceptibility to diabetes and kidney disease development in the various
models of diabetes.
1.Introduction
Diabetic nephropathy is one of the major long-term micro-
vascular complications and is the major cause of morbidity
and premature mortality in individuals with type 2 diabetes
mellitus. End-stage renal disease (ESRD) in patients with
type 2 diabetes has increased dramatically worldwide during
the last few decades, and diabetes is associated with worse
survival among patients undergoing dialysis [1–3]. The
pathogenesis of diabetic nephropathy includes both meta-
bolic and hemodynamic factors [4]. A large number of can-
didate genes have been analyzed, both regarding initiation
and progression but still are weak predictors of nephropathy
in patients with type 2 diabetes. Experimental models of
type 2 diabetes with nephropathy may oﬀer a key to a
better understanding of this complication in a multifactorial
disease such as type 2 diabetes. Several experimental models
have been developed to try to mimic human type 2 diabetes
[5]. It seems that the ideal animal model for DN research
in type 2 diabetes should have human-like kidney anatomy,
hemodynamics, and physiology; develop the human type 2
characteristics and complications; allow studies in chronic
stableDN,andallowmeasurementofrelevanthemodynamic
and biochemical parameters. However, it is diﬃcult to
generate a single-mouse model that recapitulates all of the
features of established human diabetic nephropathy [6]. In
2003, the lack of reliable mouse models for studying severe
DN prompted the National Institute of Diabetes and Diges-
tive and Kidney Diseases (NIDDK) to fund a consortium for
the development and phenotyping of new diabetic mouse
models that would resemble human DN more closely.
The Animal Models of Diabetic Complications Con-
sortium (AMDCC) deﬁned criteria for validating murine
modelsofhumandiabetesanddiabeticcomplications:>50%
decline in GFR over the lifetime of the animal, >10-fold
increase in albuminuria compared with controls for that2 Experimental Diabetes Research
strain at the same age and gender, and pathology of kidneys
(advanced mesangial matrix expansion, ± nodular sclerosis
mesangiolysis,anydegreeofarteriolarhyalinosis,glomerular
basement membrane thickening by >50% over baseline and
tubulointerstitial ﬁbrosis) [7]. The purpose of this paper is
to summarize the features of the well-established and newer
models of experimental nephropathy and their similarities to
DN in patients with type 2 diabetes. There are many simi-
larities in kidney disease ﬁndings in animal models of type
1 and type 2 diabetes, like in humans, which will not be
discussed in the paper. Exacerbation of diabetic kidney
disease by manipulations of the renin-angiotensin system
such as renin overexpression [8], knockout of the bradykinin
B2 receptor [7], or decorin deﬁciency [9] that have been
studied so far in models of type 1 diabetes will not be
discussed here, but the approaches are likely to be useful for
t y p e2d i a b e t e sa sw e l l .
2.DiabeticNephropathy inHumans
In 1959, Gellman et al. [10] ﬁrst reported ﬁndings in renal
biopsies from patients with diabetic kidney disease and their
clinical correlates. Before this was studied, the renal pathol-
ogy in patients with diabetes mellitus had only been de-
scribed systematically from autopsy ﬁndings. The initial
changes of DN are glomerular hypertrophy, mild mesangial
expansion (matrix), and thickening of the glomerular capil-
larywalls(Figure 1).Thesechangesaremoreevidentbyelec-
tron microscopy. When the disease progresses, there is also
an increase in mesangial expansion; this mesangial matrix
increase is deﬁned as an increase in extracellular material
in the mesangium such that the width of the interspace
exceeds two mesangial cell nuclei in at least two glomerular
lobules. As the disease progresses, there may be formation
of nodules in the glomerular tuft. The nodules have variable
size in a same glomerulus and aﬀect some portions of the
glomeruli, a pattern referred to as nodular diabetic glomeru-
losclerosis or Kimmelstiel-Wilson nodules (Figure 1). The
presence of these nodules, large and small, some laminates,
with variable size and distribution in the glomeruli, are
“virtually” pathognomonic of DN, although similar nodules
have been described as “idiopathic” in nondiabetic patients
[11–13]. InDN, the glomerulipresent increase ofthe mesan-
gial intercapillarymatrix, with progressive thickening of cap-
illary walls and later evolution to global glomerulosclerosis.
Other two glomerular lesions, called “insudative lesions”
(similar to arteriolar hyalinosis), are capsular drop and glom-
erular hyalinosis. The ﬁrst is a homogenous hyaline deposit,
in the Bowman’s capsule. Usually this deposit is rounded or
elongated, and its presence is highly suggestive of DN [14].
Glomerular hyalinosis is caused by a formation of a
hyalin cap or a ﬁbrin cap by accumulated plasma compo-
nents in the peripheral segments of the tuft. In many typical
DN cases, microaneurysms, produced by mesangiolysis, are
evident. In tubules, there are nonspeciﬁc changes: reabsorp-
tion of protein droplets, interstitial ﬁbrosis, and tubular
atrophy. In vessels, usually there are notorious changes; the
most characteristic lesion is intimal hyaline thickening of
arterioles. Arteriolar lesions may involve any arteriole. Dem-
onstration of arteriolar hyalinosis in both the aﬀerent and
eﬀerent arterioles is virtually pathognomic of DN. Intimal
ﬁbrosis of the arteries is typical of DN, but this feature is not
pathognomic because intimal ﬁbrosis occurs in other diseas-
es as well [15].
3. ClassicalModels of Nephropathy in
Type2Diabetes
3.1. LepRdb/LepRdb (db/db). The ﬁrst described mutation in
m i c et h a tr e s e m b l e dd i a b e t e sm e l l i t u si nh u m a n so c c u r r e d
in an inbred mouse strain (C57BL/Ks) in 1966 [16]. The
diabetic mutant is similar to the obese mutant in appearance
[17], and the diabetic gene is transmitted as an autosomal
recessivetraitresultingfromamutationoftheleptinreceptor
[16], leading to abnormal splicing and defective signaling of
the adipocyte-derived hormone leptin [18]. Kidney function
in mice with the db/db mutation on the C57BL/KS back-
ground has been intensively investigated and exhibits some
features similar to early human diabetic nephropathy, class I
to III. This model is widely used as a model of kidney disease
and morbid obesity in type 2 diabetes (Figure 2). DN in the
C57BL/KsJ(db/db) mouse is initially expressed as increased
urinary albumin excretion at the age of 8 weeks without
evidence of glomerular lesions by light microscopy [19].
Kidney hypertrophy has been noted in db/db mice at
the age of 16wk [20–22]. Glomerular hypertrophy has been
measured by a digital planimeter using standard measure-
ments of glomerular tuft areas at various ages of the db/db
and db/m mice [23, 24]. Glomerular surface area was in-
creasedat8wkofageandremainedincreasedat25wkofage.
The time course of mesangial matrix expansion was de-
scribed by Cohen et al. [23]. At 12wk of age and after 4–6wk
ofhyperglycemia,atwofoldincreaseinmesangialmatrixwas
noted. After 16wk of age, a consistent threefold increase in
mesangial matrix expansion was reported. At 5-6mo of age,
diabetic mice had larger glomeruli with increased mesangial
matrix by periodic acid-Schiﬀ (PAS) staining (Figure 2). By
18–20mo of age, the mesangial matrix and glomerular en-
largement became more pronounced and thickening of the
glomerular basement membrane (GBM) was notable. In the
oldest diabetic mice studied (16–22mo of age), strikingly
large subepithelial nodular densities were observed along
with foot process fusion [24]. Albuminuria according to
some studies is not very progressive in this model [24]. How-
ever, in the C57 background, which is generally resistant to
kidney disease, albumin-creatinine ratio, in our experience,
increases substantially as the animals age from 8 to 32 weeks
of age [19].
3.2. Lepob/Lepob. The ob/ob recessive obese mouse carries a
mutation in leptin, the ligand for the leptin receptor [26].
The Lepob mutation exists in diﬀerent strains such as DBA2/J
and C57BL/6J and FVB strains [27]. Renal structure and
function in C57BL/6J ob/ob mice is said to be relatively mild.
Chua et al. observed increased mesangial matrix expansion
in FVB ob mice [27] .T h i sm o d e li sn o to f t e nu s e dc u r r e n t l y .Experimental Diabetes Research 3
(a) (b) (c)
(d) (e)
Figure 1: Established DN in humans: (a) glomerular basement membrane thickening by electron microscope. (b) Glomerular nodules in
DN with intensively positive staining by methenamine silver. Nodular glomerulosclerosis: (c) hematoxilin eosine staining, (d) periodic acid-
schiﬀ stain demonstrates the mesangial nodules and esclerosis glomerular. (e) nodular diabetic glomerulosclerosis by Masson’s trichrome
staining, (Magniﬁcation ×400) in collaboration with Dr. Javier Gimeno.
(a) (b) (e)
(f) (d) (c)
Figure 2: Glomerular histopathology in eNOS−/− db/db mice. Representative glomerular lesions of diabetic mouse kidneys at 24–26wk:
control(a);db/db(bande);eNOS−/− (c)eNOS−/− db/db(dandf).(f)Arteriolarhyalinosis(bigarrow)andearlynodularglomerulosclerosis
(small arrow) in eNOS−/− db/db mice (periodic acid-Schiﬀ). Reprinted with permission from the Journal of the American Society of
Nephrology [25].
3.3. New Zealand Obese Mice. New Zealand obese (NZO)
mice are an inbred strain originally selected in New Zea-
land for polygenic obesity, and it is known to have obe-
sity/diabetes as aresultofQTLson chromosomes1, 2, 4, 5,6,
7, 11, 12, 13, 15, 17, and 18 [28–30] .M i c ea r ea l s op r o n et o
autoimmune disease as the kidneys exhibit light microscopic
features that resemble lupus nephritis, not just diabetes
lesions. The changes include glomerular proliferation, me-4 Experimental Diabetes Research
sangial deposits, mild basement membrane thickening, and
glomerulosclerosis [31, 32]. Eosinophilic nodules may be
seen in some glomeruli, with occasional hyalinization of the
glomerular arterioles and healing arteriolar inﬂammation
[31, 32].
3.4. Agouti Mutation. The agouti gene is expressed during
the hair-growth cycle in neonatal skin where it functions as
a paracrine regulator of pigmentation [33, 34]. The secreted
agouti protein antagonizes the binding of the a-melanocyte-
stimulating hormone to its receptor (melanocortin 1 recep-
tor) on the surface of hair bulb melanocytes, causing alter-
ations in intracellular cAMP levels [33, 34]. Widespread,
ectopic expression of the mouse agouti gene is central to
the yellow obese phenotype, as demonstrated by the molec-
ular cloning of several dominant agouti mutations and the
ubiquitous expression of the wildtype agouti gene in trans-
genic mice. The hypothalamus and adipose tissue are bio-
logically active target sites for agouti in the yellow obese
mutantlines[33,34].ReportsofalbuminuriaindiabeticKK-
Ay mice suggest this mutation may be useful for the study
ofnephropathy.Moreover,thepathologicalchangesinglom-
eruli from KK-Ay/TA mice are consistent with those in the
early stage of human diabetic nephropathy [35]. This animal
model of type 2 diabetes has, therefore, been proposed to
examine the early stages of diabetic nephropathy [35]. It
should be noted, however, that with aging diabetic KK-Ay
micedevelopspontaneoushydronephrosis,extremelydilated
pelvis, and thinned atrophied parenchyma [36].
3.5. High-Fat Diet. A high-fat diet (HFD) provides a
commonly used approach to induce obesity and insulin
resistance in C57BL6 mice [37] and is also useful to study
accelerated atherosclerosis associated with diabetes [38, 39].
Surwit et al. showed that genetic diﬀerences in the metabolic
response to fat are more important in the development of
obesity and diabetes than the increased caloric content of
ahigh-fatdiet[37].HFDtoC57BL/6miceinducesmajorsys-
temic alterations compatible to human metabolic syndrome,
including obesity, hyperglycemia, hyperinsulinemia, hyper-
triglyceridemia, and hypertension [40]. After the onset of
metabolic syndrome, mice on an HFD developed increased
UAE and glomerular lesions with the accumulation of extra-
cellular matrix protein. Furthermore, renal pathophysiolog-
ical alterations, including lipid accumulation, macrophage
inﬁltration, increased oxidative stress, and impaired sodium
handling were observed in the mice on an HFD [40].
4.NewModelsof DN
Previousanimalmodelsofdiabetickidneydiseasehaveman-
ifested albuminuria and early renal pathologic changes such
as glomerular basement thickening and mesangial expansion
but with only minimal or inconsistent expression of other
characteristic histopathologic features such as arteriolar hya-
linosis and nodular glomerulosclerosis. The failure of previ-
ous models to manifest these lesions prompts the develop-
ment of new models of DN (Table 1).
4.1. Db/db eNOS−/−. Targeting Nos3, the gene encoding
eNOS, or endothelial nitric oxide synthase was found to
result in nephropathic changes in mouse models of type 1
and type 2 diabetes that mimic many aspects of human
disease due to inhibition of nitric oxide formation [25].
C56BL/KS Db/db eNOS−/− mice developed striking albu-
minuria and characteristic pathologic changes of DN such
as mesangiolysis, microaneurysms, and increased mesangial
matrix expansion. In addition, nodular lesions (nodular
glomerulosclerosis) and globally sclerotic glomeruli (diﬀuse
glomerulosclerosis) were reported at 26 weeks [25, 41]. This
model also exhibited remarkably decreased GFR on the basis
of inulin clearance and serum creatinine measurements [25].
Studies in eNOS−/− mice demonstrated that this KO model
develops moderate systemic hypertension. The increase in
SBP was slightly greater in diabetic db/db eNOS−/− mice,
although the results did not reach statistical signiﬁcance
[25]. These studies demonstrated that db/db eNOS−/− mice
exhibit signiﬁcant albuminuria and glomerular pathology
thatparallelthelaterphaseofDNinpatientswithtype2dia-
betes including arteriolar hyalinosis, mesangial expansion,
thickening of GBM, and focal segmental and early nodular
glomerulosclerosis [25, 41]( Figure 2). This model should
prove useful for studying the role of endothelial dysfunction
in development of DN and in facilitating the development of
new diagnostic and therapeutic interventions.
4.2. NONcNZO10/LtJ. AN O N c N Z O 1 0 / L t Ji sa ni n b r e d
congenic strain derived from a cross between the Nonobese
Nondiabetic (NON/LtJ) strain and the New Zealand Obese
(NZO/HlLt) mouse, which provides a model of polygenic
type 2 diabetes [29, 30, 42]. After approximately 8 mo of age,
these mice also develop signiﬁcant and progressively in-
creasing albuminuria, with urine albumin-creatinine ratios
>1000μg/mg after 1yr. Glomerular histopathology is im-
pressively abnormal. In addition to glomerulosclerosis, how-
ever, there were features that are atypical of diabetic neph-
ropathy. These included intraglomerular capillary thrombi
and lipid deposition, nephritis, and evidence of Ig deposi-
tion. These features suggest that this may not be a good
model for studying DN [29, 30, 42].
4.3. BTBRob/ob. Clee et al. characterized a mouse model of
insulin resistance that develops in the progeny of the BTBR
(black and tan, brachyuric) mouse strain crossed with
C57BL/6 mice [43, 44]. BTBR mice are naturally hyperinsu-
linemic when compared with C57BL/6 mice, and BTBR ×
C57BL/6 F1 mice are substantially insulin resistant [44, 45].
When the ob/ob mutation is placed on a BTBR background,
the mice are initially insulin resistant with elevated insulin
levels, pancreatic islet hypertrophy, and marked hyper-
glycemia by 6 weeks of age [46].
The BTBR ob/ob mouse model of DN comes close to
meeting all of the proposed criteria of the AMDCC (albu-
minuria, pathologic changes) and oﬀers several important
advantages compared with existing DN models. The most
important of these is the degree to which it supposedly re-
produces the essential structural and functional features ofExperimental Diabetes Research 5
Table 1: Some new models studied for diabetic nephropathy.
Animal model Strain Kidney pathology References
Db/db eNOS−/− BKS
Signiﬁcant albuminuria, decreased
GFR, markedly increased mesangial
matrix expansion, glomerular basement
membrane thickening, arteriolar
hyalinosis, mesangiolysis, nodular
glomerulosclerosis, and
tubulointerstitial injury
Zhao et al. [25]a n d
Mohan et al. [41]
NONcNZO10/LtJ NON/LtJ + NZO/HlLt
Albuminuria, glomerulosclerosis,
intraglomerular capillary thrombi and
lipid deposition, nephritis, and Ig
deposition
Reifsnyder and Leiter
[29, 30]
BTBRob/ob BTBR
Albuminuria, loss of podocytes,
extensive mesangial expansion,
mesangiolysis, basement membrane
thickening, and interstitial ﬁbrosis
Hudkins et al. [46]
GIPRdn transgenic CD1
Renal, podocyte and glomerular
hypertrophy, mesangial expansion, and
matrix accumulation,
glomerulosclerosis, proteinuria, and
tubulointerstitial lesions
Herbach et al. [49]
GLUT1 transgenic C57BL6/J
Albuminuria, glomerular hypertrophy,
mesangial expansion, and
glomerulosclerosis
Wang et al. [50]
podIR knockout (podocin
or nephrin promoter)
Mixed genetic
background (C57BL/6,
129/SV, and FVB)
A l b u m i n u r i a ,l o s so ff o o tp r o c e s s
structure, podocyte apoptosis, increased
glomerular matrix, thickened GBM,
glomerulosclerosis, and kidney sclerosis
Welsh et al. [52]
human diabetic glomerular injury. Glomerular hypertrophy,
marked expansion of mesangial matrix, mesangiolysis, and
capillary basement membrane thickening have been identi-
ﬁed in this model (Figure 3). Loss of podocytes (Figure 4)i s
also present in the BTBR ob/ob model [46].
The functional consequence of these changes in hu-
mans—marked proteinuria—also is present in this mouse
model with a 10-fold increase in urinary protein excretion
compared with controls [46] .S e c o n d ,t h em o d e li sr o b u s t
and progressive: BTBR ob/ob mice uniformly develop fea-
tures of DN and do so in a predictable time course in which
podocyte loss is already detectable by 8 weeks of age and
persists throughout the disease. Signiﬁcant proteinuria is
detectable as early as 8 weeks of age, corresponding with de-
tectable podocyte loss, although it can be detected in some
mice at even earlier ages, albeit without achieving statistical
signiﬁcance, when comparing 4-week-old cohorts with con-
trols.
Mesangiolysis is also an early feature of the disease, de-
tectable in approximately 10% of glomeruli at 8 weeks of age
and coincides with detectable expansion of the mesangial
matrix. These mesangial alterations are progressive with
detectable expansion of the mesangial matrix. The BTBR
ob/ob mouse is among the very few models in which pro-
nounced mesangial expansion and mesangiolysis resembling
advanced human DN predictably develop [46]. Third, DN
develops more rapidly in BTBR ob/ob mice compared with
models of leptin receptor deﬁciency (db/db mice) or most
other mouse models currently used to study DN [7], which
oftenrequirefrom30to50weeksormoretodeveloprelevant
lesions. The relatively rapid onset allows opportunities for
testing therapeutic strategies aimed at halting or ameliorat-
ing DN in a much shorter time span. BTBR ob/ob mice
developaconstellationofabnormalitiesthatcloselyresemble
advanced human DN more rapidly than most other murine
models, making this strain particularly attractive for testing
therapeutic interventions [46].
4.4. GIPRdn Transgenic. Transgenic mice, expressing the
mutated human glucose-dependent insulinotropic polypep-
tidereceptor(GIPR),weregeneratedunderthecontrolofthe
r a tp r o i n s u l i n2g e n ep r o m o t e ri np a n c r e a t i cb e t ac e l l s[ 47].
These GIPRdn transgenic mice exhibit an early disturbance
in pancreatic islet development (severe reduction of beta-
cell mass, disturbed composition of islets, and decreased islet
neogenesis), diminished insulin secretion, and early-onset
diabetes mellitus, without obesity or insulin resistance. In
type 2 diabetic patients, a major abnormality is reduced
insulinotropic action of GIP [48], as well as reduced volume
density and mass of beta cells in the pancreas [47]. There-
fore, GIPRdn transgenic mice resemble important aspects of
h u m a nt y p e2d i a b e t e sm e l l i t u s .
GIPRdn transgenic mice develop progressive diabetes-
associated kidney lesions with many parallels to the human6 Experimental Diabetes Research
(a) (b) (e)
(d)
(c)
Figure 3: Ultrastructural changes in BTBR ob/ob mice resemble human DN. (a and b) Electron microscopy of glomeruli of 22-week-old
BTBR ob/ob mice shows qualitatively good preservation of foot processes overall. There is an increased mesangial matrix and evidence of
mesangiolysis with fraying of the mesangial/capillary interface (arrows) in (b). (c and d) Basement membranes are thickened, and there
is focal eﬀacement of foot processes in BTBR ob/ob mice (c) when compared with BTBR WT mice (d). There is no evidence of immune
deposits. (e) Advanced human DN, occurring after one or more decades of diabetes, also shows marked mesangial matrix accumulation
with similar fraying of the mesangial/capillary interface as seen in BTBR ob/ob mice (double arrows). Reprinted with permission from the
Journal of the American Society of Nephrology [46].
(a) (b)
Figure 4: Podocyte loss in BTBR ob/ob mice. BTBR ob/ob mice have reduced podocyte number. (a and b) There is a reduction in podocyte
number assessed by WT-1 staining, in BTBR ob/ob (a) compared with BTBR WT (b) mice. Reprinted with permission from the Journal of
the American Society of Nephrology [46].
disease, that is, renal, glomerular, and podocyte hypertrophy,
thickening of the GBM, reduction of the glomerular density
of podocytes, progressive glomerulosclerosis albuminuria,
and tubulointerstitial changes. This experimental model,
may serve as an excellent new model for studying the
pathogenesis of DN, the sequence of structural, functional,
and molecular changes of glomerular cells, and for testing
the eﬃcacy of new therapies [49].
4.5. GLUT-1 Transgenic. Heilig’s group recently published
the phenotype of transgenic GLUT1-overexpressing mice
(GT1S). This is an intriguing model designed to characterize
the roles of GLUT1 and intracellular glucose in the develop-
ment of glomerular disease without diabetes [50]. Kidneys of
GT1S mice overexpressed GLUT1 in glomerular mesangial
cells and small vessels without increased expression in renal
tubules. GT1S mice were neither diabetic nor hypertensive.
Glomerular GLUT1, glucose uptake, mean capillary diam-
eter, and mean glomerular volume were all increased in
the GT1S mice. The transgenic glomeruli revealed diﬀuse
mesangial expansion on light microscopy, occasionally with
nodular features, although the nodules were more cellular
and do not really replicate the human Kimmelstiel Wilson
nodules. Moderately severe glomerulosclerosis (GS) was
found by 26 weeks of age in GT1S mice, with increased
glomerular Type IV collagen and ﬁbronectin. Modest
increases in GBM thickness and albuminuria were detected
with podocyte foot processes largely preserved, in the
absence of podocyte GLUT1 overexpression [50]. Activation
of glomerular PKC, along with increased TGFβ1, VEGFR1,
VEGFR2, and VEGF was all detected in glomeruli of GT1S
mice, likely contributing to GS. The transcription factor
NF-κB was also activated. Overexpression of glomerular
GLUT1, mimicking the diabetic GLUT1 response, produced
numerous features typical of diabetic glomerular disease,Experimental Diabetes Research 7
without diabetes or hypertension. This suggested that the
GLUT-1 transporter overactivity plays an important role
in the development of DN possibly by locally increasing
glucose uptake at the glomerular level. In this respect, this
model oﬀers a strong evidence for intracellular glucose in the
development of glomerulosclerosis [50].
4.6.PodIRKnockout. Todeterminewhetherinsulinsignaling
in podocytes aﬀects glomerular function in vivo, Welsh’s
group generated mice with speciﬁc deletion of the insulin
receptor from their podocytes (podIRKO). PodIRKO mice
were generated by crossing ﬂoxed insulin receptor mice with
podocyte-speciﬁc Cre recombinase mice driven by both the
nephrin and podocin promoters [51, 52]. Detailed renal
evaluation at 3 weeks of age was normal in podIRKO mice
with no abnormality identiﬁable using either light or elec-
tron microscopic analysis. At 5 weeks of age, both podIRKO
models (nephrin and podocin promoter) started to develop
albuminuria accompanied with loss of the podocyte foot
process structure detected by electron microscopy [52].
At 8 weeks of age, signiﬁcant levels of albuminuria and
histological changes such as extensive loss of foot process
structure and podocyte apoptosis were present in podIRKO.
Furthermore, at 13 weeks of age, podIRKO mice had
increased amounts of glomerular matrix, thickened GBM,
and increased levels of glomerulosclerosis [52]. As they
aged, these pathological features became more prominent,
with some of the podIRKO mice developing macroscopically
shrunken and sclerosed kidneys. These animals develop
signiﬁcant albuminuria together with histological features
that recapitulate DN, but in a normoglycemic environment.
These novel ﬁndings reveal the critical importance of
podocyte insulin sensitivity for kidney function [52].
5.Ge neticBac k gr o undasaM od iﬁ e ro f
DiabeticKidneyDisease
Gurley and others have emphasized the importance of
the genetic background in kidney disease development in
diabetic mice [7]. Their initial studies focus on STZ-induced
diabetes but they are relevant to most models of diabetes.
They reported among ﬁve common inbred mouse strains a
hierarchical response of blood glucose levels to STZ-induced
diabetes (DBA/2>C57BL/6>MRL/Mp>129/SvEv>BALB/c).
In all ﬁve strains, males demonstrated much more robust
hyperglycemia with STZ than females. STZ-induced diabetes
was associated with modest levels of albuminuria in all of
the strains, but was greatest in the DBA/2 strain, which
also had the most marked hyperglycemia [53]. Observed
r e n a ls t r u c t u r a ld i ﬀerences between the strains were limited
to mesangial expansion, but the strong correlation between
high blood glucose and mesangial size expansion suggests
that the size diﬀerences were caused by the diﬀerences in
b l oodgl u c o s el ev el s .Th ed i ﬀerences in the responses to STZ-
induced diabetes suggest that DBA/2 is the most susceptible
to diabetic nephropathy and is most likely the most useful
platform for model development [53]. It is important to
emphasize the relative resistance to diabetic nephropathy of
the widely used C57BL/6 mouse [7]. The Mouse Phenome
Database is a useful source for comparative data of basal
metabolic parameters distinguishing the more commonly
used inbred strains (http://phenome.jax.org/). This website
contains albumin-creatinine ratio data for males and females
of 30 inbred strains [7].
6. Conclusions
The use of experimental animal models of DN has pro-
vided valuable information regarding some aspects of DN.
Classical experimental models of type 2 DN have been
available. However, for some time these models have not
been able to reproduce features of advanced DN such
as nodules in the glomerular tuft or glomerulosclerosis.
Moreover, information on progressive decline in GFR is
often missing in these models. In particular, through the
eﬀorts of the AMDCC investigators as well as others,
using genetic breeding and other means to enhance disease
severity, the characteristic features of experimental diabetic
nephropathy are becoming more apparent. The importance
of genetic background on susceptibility and resistance to
kidney disease is increasingly recognized as a key factor.
Data from the Diabetic Complications Consortium group
hasbeenveryhelpfulfortheresearchersbycreatingawebsite
that includes a protocol for validation of mouse models
of diabetic nephropathy and updated characterization of
diﬀerent diabetic models.
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